Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-satoreotide trizoxetan dose confirmation in GEP-NET
NCT03220217Phase 2Completed
- Sponsor
- Ipsen
- Start
- Sep 2017
- Primary completion
- Jul 2019
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of satoreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (3 arms), sponsored by Ipsen. Primary endpoint: Relative Lesion Counts Presented by Combination of Injected Peptide/Radioactivity Dose Ranges. Started Sep 2017; status: completed.
02
Drugs
satoreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03220217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220217.